Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationEBIATLeasesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Shares IssuedShares OutstandingShares Repurchased
Ratios

Anika Therapeutics (ANIK) Accumulated Depreciation & Amortization: 2010-2025

Historic Accumulated Depreciation & Amortization for Anika Therapeutics (ANIK) over the last 5 years, with Jun 2025 value amounting to $50.2 million.

  • Anika Therapeutics' Accumulated Depreciation & Amortization was N/A to $50.2 million in Q2 2025 from the same period last year, while for Jun 2025 it was $188.1 million, marking a year-over-year change of. This contributed to the annual value of $46.3 million for FY2024, which is 5.22% up from last year.
  • Per Anika Therapeutics' latest filing, its Accumulated Depreciation & Amortization stood at $50.2 million for Q2 2025, which was up 5.29% from $47.6 million recorded in Q1 2025.
  • In the past 5 years, Anika Therapeutics' Accumulated Depreciation & Amortization ranged from a high of $50.2 million in Q2 2025 and a low of $39.6 million during Q4 2021.
  • For the 3-year period, Anika Therapeutics' Accumulated Depreciation & Amortization averaged around $47.0 million, with its median value being $47.0 million (2024).
  • Per our database at Business Quant, Anika Therapeutics' Accumulated Depreciation & Amortization increased by 16.67% in 2022 and then fell by 4.75% in 2023.
  • Quarterly analysis of 5 years shows Anika Therapeutics' Accumulated Depreciation & Amortization stood at $39.6 million in 2021, then grew by 16.67% to $46.2 million in 2022, then decreased by 4.75% to $44.0 million in 2023, then grew by 5.22% to $46.3 million in 2024, then reached $50.2 million in 2025.
  • Its Accumulated Depreciation & Amortization stands at $50.2 million for Q2 2025, versus $47.6 million for Q1 2025 and $46.3 million for Q4 2024.